Physician profile
Dave Hollander
NPI 1629015219
$3,629.17
in general payments reported to CMS, 2019-2025
24 companies · $420 in 2025
The $420 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $405 · 2021: $839 · 2022: $652 · 2023: $437 · 2024: $500 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,356.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $542.63 | 2019-2025 | Austedo Xr, Austedo Xr |
| Amneal Pharmaceuticals LLC | $376.83 | 2022-2025 | Crexont, Ongentys, Rytary |
| Pfizer INC. | $350.92 | 2023-2025 | |
| Abbvie INC. | $345.66 | 2021-2023 | |
| Celgene Corporation | $289.68 | 2021-2023 | Zeposia |
| Biogen, INC. | $198.98 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $176.62 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $140.14 | 2022 | |
| Neurocrine Biosciences, INC. | $138.52 | 2022-2025 | Ingrezza, Ongentys |
| Ge Healthcare | $137.75 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $131.54 | 2019-2021 | |
| Argenx US, INC. | $129.64 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Allergan, INC. | $124.00 | 2020 | |
| Grifols USA, LLC | $121.44 | 2019-2025 | Gamunex-C |
| Biohaven Pharmaceuticals, INC. | $117.20 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tanabe Pharma America, INC. | $67.38 | 2020-2025 | Radicava |
| Eisai INC. | $66.54 | 2023-2025 | |
| Livanova USA, INC. | $49.28 | 2021-2022 | |
| Avion Pharmaceuticals | $36.54 | 2021-2022 | |
| Janssen Biotech, INC. | $24.09 | 2025 | |
| Alnylam Pharmaceuticals INC. | $20.42 | 2023 | Givlaari |
| Takeda Pharmaceuticals U.S.A., INC. | $15.61 | 2020 | |
| Genzyme Corporation | $14.49 | 2024 | |
| Amgen INC. | $13.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dave Hollander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.